Ergotamine

Do not use within 24 hours of each other due to risk of prolonged vasospastic reactions with potentially additive vasospastic effects.

Do not use almotriptan malate and ergotamine within 24 hours of each other due to risk of prolonged vasospastic reactions.

Ergotamine-containing drugs cause prolonged vasospastic reactions. Use within 24 hours of eletriptan hydrobromide is contraindicated due to additive effects.

Co-administration associated with acute ergot toxicity characterized by vasospasm and ischemia of extremities and other tissues including central nervous system.

Coadministration associated with acute ergot toxicity characterized by vasospasm and ischemia of extremities and central nervous system.

Co-administration associated with acute ergot toxicity characterized by vasospasm and ischemia of central nervous system and tissues.

Ergotamine-containing drugs cause prolonged vasospastic reactions that may be additive with frovatriptan. Use within 24 hours of each other is contraindicated.

Coadministration is contraindicated. Itraconazole increases plasma concentrations of ergot alkaloids, potentially increasing pharmacologic effects and adverse reactions.

Coadministration of ketoconazole with ergotamine is contraindicated.

Mifepristone increases ergotamine exposure; concomitant use is contraindicated due to narrow therapeutic range.

Ergotamine-containing drugs cause prolonged vasospastic reactions that may be additive with naratriptan. Use within 24 hours of each other is contraindicated.

Nitroglycerin markedly decreases first-pass metabolism of ergotamine, increasing bioavailability. Ergotamine can precipitate angina pectoris. Avoid concomitant use.

Ergotamine-containing drugs cause prolonged vasospastic reactions with additive effects. Use within 24 hours is contraindicated.

Ergot-containing drugs cause prolonged vasospastic reactions. Use within 24 hours of rizatriptan benzoate is contraindicated due to potentially additive vasospastic effects.

Ergotamine-containing drugs cause prolonged vasospastic reactions that may be additive with sumatriptan. Use within 24 hours of each other is contraindicated.

Ergotamine-containing drugs cause prolonged vasospastic reactions; additive effects contraindicate use within 24 hours of sumatriptan succinate.

Ergot-containing drugs cause prolonged vasospastic reactions. Coadministration within 24 hours is contraindicated due to additive effects.

Ergotamine-containing drugs cause prolonged vasospastic reactions that may be additive with zolmitriptan. Use within 24 hours of each other is contraindicated.

Macrolide products have been observed to cause acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia. Careful monitoring advised.

Nitroglycerin increases bioavailability of ergotamine and ergotamine can precipitate angina. Avoid concomitant use or monitor for ergotism symptoms.

Deferasirox may induce CYP3A4 resulting in decreased ergotamine concentration. Monitor for reduced effectiveness.

Methylene blue inhibits CYP3A4/5 metabolism. Ergotamine has narrow therapeutic index; clinical relevance unknown but concurrent use requires caution.

Nitroglycerin decreases first-pass metabolism of ergotamine, increasing bioavailability. Ergotamine may precipitate angina pectoris; monitor or avoid concomitant use.

Sensitive CYP3A substrate with narrow therapeutic index. Dose may need reduction when coadministered with palbociclib.

In vitro data of benzodiazepines suggest possible drug interaction with triazolam. Caution recommended.